Fig. 5: Measurement of cell viability and PKC/ERK phosphorylation in myoblasts treated with simvastatin in combination or not with CB1 drugs. | Cell Death & Disease

Fig. 5: Measurement of cell viability and PKC/ERK phosphorylation in myoblasts treated with simvastatin in combination or not with CB1 drugs.

From: Dysfunctional endocannabinoid CB1 receptor expression and signaling contribute to skeletal muscle cell toxicity induced by simvastatin

Fig. 5

A Bar graph with individual points reporting the cell viability measured in scramble (gray) or antagomiR-152 (orange) transfected myoblasts treated with simvastatin alone or in combination with ACEA (1 µM), rimonabant (1 µM) or GF10923X (5 µM). Each bar is the mean ± S.E.M. from at least 5 independent biological samples. * = p ≤ 0.05; ** = p ≤ 0.01 versus the indicated experimental group. B Representative blots showing phosphorylation of PKC (pPKC) and ERK (pERK) in C2C12 treated with simvastatin (30 µM) in combination or not with ACEA (1 µM) and rimonabant (1 µM). C Bar graph with individual points reporting the effect of simvastatin (30 µM) in combination or not with ACEA (1 µM) and rimonabant (1 µM) on the phosphorylation of PKC (pPKC) and ERK (pERK) in C2C12 cells, as obtained from western blots such as those represented in panel (B). Each bar is the mean ± S.E.M. from 3 independent biological samples. * = p ≤ 0.05; ** = p ≤ 0.01; *** = p ≤ 0.005 ; **** = p ≤ 0.0001 versus the indicated experimental groups; ± = p ≤ 0.005 versus the internal (scramble or simv) veh group.

Back to article page